Endoscopic Ultrasound-Guided Chemoablation for Pancreatic Cysts

(ERASE-Chemo Trial)

This trial explores a new treatment method for individuals with pancreatic cysts, which can potentially lead to pancreatic cancer. The treatment uses an endoscope (a thin tube with a camera) to deliver chemotherapy drugs, specifically Gemcitabine Hydrochloride and Paclitaxel, directly into the cyst. This aims to destroy abnormal cells while minimizing impact on the rest of the body. Individuals diagnosed with a pancreatic cyst who cannot undergo surgery might be suitable candidates for this trial. This approach could provide a less invasive option for managing these cysts. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to the development of potentially effective therapies.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Research has shown that EUS-guided chemoablation using gemcitabine and paclitaxel is generally safe for treating pancreatic cysts. One study found that 67% of patients had their cysts completely removed 12 months after treatment. Additionally, long-term results indicated that 87% of patients remained cyst-free for three to five years.

Gemcitabine has proven effective in destroying tumor cells and is considered safe in this procedure. Similarly, paclitaxel is safe for comparable treatments, yielding good results with few serious side effects.

Unlike the standard care for pancreatic cysts, which often involves surgical removal or monitoring, the endoscopic ultrasound-guided chemoablation with gemcitabine and paclitaxel offers a minimally invasive approach. Researchers are excited about this treatment because it directly targets the cysts via chemoablation, potentially reducing the need for surgery and its associated risks. This method combines the precision of endoscopic ultrasound with potent anticancer agents delivered directly to the site, which could lead to more effective cyst management and better patient outcomes.

Research has shown that endoscopic ultrasound (EUS)-guided chemoablation, using gemcitabine and paclitaxel, holds promise for treating pancreatic cysts. In this trial, participants will undergo EUS-guided chemoablation with these drugs. Studies have found that this method can make the cysts disappear or shrink significantly. Patients receiving this treatment often require fewer medical check-ups, and the cysts are less likely to return or become cancerous. EUS-guided chemoablation is considered safe and effective, offering a less invasive alternative to surgery for managing pancreatic cysts. By delivering gemcitabine and paclitaxel directly into the cysts, this approach targets and kills abnormal cells while minimizing side effects on the rest of the body.¹²⁶⁷⁸